Consequently, changes in renal function are not anticipated to impact the elimination of mepolizumab. Likewise, since mepolizumab is degraded by widely distributed proteolytic enzymes, not restricted to hepatic tissue, hepatic function does not therefore influence the elimination of mepolizumab. For this reason, no specific renal or hepatic impairment studies were conducted.